IMMX Stock Analysis: Buy, Sell, or Hold?
IMMX - Immix Biopharma, Inc. Common Stock
$8.62
-0.49 (-5.38%)
▼
5d:
-3.25%
30d:
+5.77%
90d:
+63.26%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
IMMX is down 9.9% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 284 OI. Call ratio: 74% View Scanner →
Strength: 7.3/10
Get Alerted When IMMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMMX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMMX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMMX is currently trading at $8.62, which is considered fair relative to its 30-day fair value range of $8.11 to $9.98.
Technical Outlook: Technically, IMMX is in a strong uptrend. Immediate support is located at $8.00, while resistance sits at $10.09. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.04 (+86.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMMX is in a strong uptrend. Immediate support is located at $8.00, while resistance sits at $10.09. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.04 (+86.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$8.11 -
$9.98
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 86.1% below Wall St target ($16.04)
Fair Price Analysis
30-Day Fair Range
$8.11 -
$9.98
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$8.00
Resistance Level
$10.09
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.11
Wall Street Target
$16.04
(+86.1%)
Share & Embed Analysis
Last updated: April 02, 2026 5:57 AM ET
Data refreshes hourly during market hours. Next update: 6:57 AM
Data refreshes hourly during market hours. Next update: 6:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMMX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gabriel S Morris
BUY
770 shares
2025-12-10
Ilya M Rachman
BUY
746 shares
2025-12-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 59 HOLD |
